Learn how a TB-500 cycle is typically structured, including common length, dosing ranges, and safety notes, plus how researchers combine it with BPC-157.
A TB-500 cycle is typically described as a 4- to 6-week protocol using roughly 2 to 5 mg per week, split into two injections during a loading phase and reduced to once weekly afterward. TB-500 is a synthetic fragment of the protein thymosin beta-4, and it is not FDA-approved for human use in the United States. The details below summarize published animal research and self-reported community protocols — not a treatment plan.
What TB-500 Is and Why Cycle Length Matters
TB-500 is a short synthetic peptide modeled on the active portion of thymosin beta-4, a protein found in nearly every human cell. Researchers study it for its ability to bind actin, encourage cell migration, and support new blood vessel formation.
Nearly all of that work has been done in animals or in cell cultures. No large randomized controlled trial has tested TB-500 in humans, so human dosing, safety, and effectiveness remain unknown.
Cycle length matters because TB-500 is discussed as something you run for a set period and then stop, rather than use indefinitely. How long that period should be is a community convention, not a research finding.
How Long a TB-500 Cycle Usually Lasts
Most TB-500 cycle length protocols that circulate online follow the same shape: a higher-dose loading phase at the start, then a lower-dose maintenance phase. Short cycles are far more common than long ones.
| Phase | Typical duration | Injection frequency | Reported weekly total |
|---|---|---|---|
| Loading | 2–4 weeks | 2 injections per week | 4–5 mg |
| Maintenance | 2–4 weeks | 1 injection per week | 2–2.5 mg |
| Extended | 8–12 weeks | 1 injection every 1–2 weeks | 1–2.5 mg |
An extended 8- to 12-week schedule appears in some forums, but it is not supported by any comparative study. Longer exposure means more injections, more cost, and more opportunities for injection-site irritation.
TB-500 is often described as staying active for several days after a dose, which is the rationale behind once-weekly maintenance injections. That estimate comes from animal pharmacokinetics, not human data.
Common Dosing Patterns During a TB-500 Cycle
There is no standard TB-500 dose. The patterns below reflect what users report in forums and what vendors print on research labels, and they vary enough that any single number should be treated as arbitrary.
- 2 mg twice weekly for 2–4 weeks — the most frequently cited starting protocol.
- 2.5 mg twice weekly for 2 weeks — a heavier loading option some users describe.
- 2 mg once weekly for 2–4 weeks — a maintenance schedule after loading.
- 1 mg once weekly for 8–12 weeks — a lower-dose, longer approach.
Subcutaneous injection is the route described in nearly every protocol. Oral TB-500 is not well documented, and there is little evidence that the peptide survives digestion intact.
Reconstitution practices matter as much as dose. Vials are typically mixed with bacteriostatic water, stored refrigerated, and used within a few weeks.
TB-500 vs. BPC-157: Comparing Cycle Protocols
TB-500 and BPC-157 are the two peptides most often mentioned together, but their cycles are not interchangeable. BPC-157 is usually run in smaller, more frequent doses over a somewhat longer window.
| Feature | TB-500 | BPC-157 |
|---|---|---|
| Typical cycle length | 4–6 weeks | 4–8 weeks |
| Common dose | 2–2.5 mg per injection | 250–500 mcg per dose |
| Injection frequency | 1–2 times per week | 1–2 times per day |
| Usual route | Subcutaneous | Subcutaneous or oral |
| FDA status for humans | Not approved | Not approved |
Both peptides are sold for laboratory research only. Neither has an approved human indication, and neither has completed the clinical trial process required for a prescription drug in the United States.
Stacking TB-500 with BPC-157 and Other Peptides
A common question is how to cycle bpc-157 and tb-500 together, since the two are frequently paired in recovery discussions. Most written protocols stagger the start dates by a week or two so that any reaction can be traced to one peptide.
Conversations about bpc-157 and tb-500 dosage for injury usually separate a loading phase from a maintenance phase for each peptide instead of doubling both at once. That approach keeps the total weekly amount closer to what appears in single-peptide protocols.
People new to this space often begin by asking what is bpc-157 and tb-500 used for before they ever compare cycle lengths. The short answer is that both are studied for tissue repair and inflammation signaling in animal models, not for any approved human use.
Pre-mixed vials marketed as GLOW or KLOW blends combine TB-500 with BPC-157, GHK-Cu, and KPV. Blend dosing is harder to control because the ratio is fixed by the vendor rather than chosen by the user.
Questions about where to buy bpc-157 and tb-500 matter because purity varies widely between suppliers. Third-party certificates of analysis are the only commonly available check, and they are not a substitute for regulatory review.
Safety, Side Effects, and Legal Status
TB-500 is not FDA-approved for human use in the United States, and it cannot legally be sold as a dietary supplement or a drug. Vials labeled "for research use only" are not manufactured under pharmaceutical quality standards.
Reported side effects in community accounts include injection-site redness, swelling, headache, and fatigue. Because these reports are uncontrolled, they cannot establish how common those effects are or whether TB-500 caused them.
There is also very little information about interactions with prescription medications, effects during pregnancy, or long-term immune response to repeated peptide injections. Anyone considering a TB-500 cycle should discuss it with a licensed healthcare professional rather than rely on forum protocols.
Practical takeaways:
- Short cycles dominate. Four to six weeks is the most commonly described TB-500 cycle, with a loading phase followed by maintenance.
- Human evidence is essentially absent. No large controlled trial has evaluated TB-500 in people.
- Stacking adds variables. Combining peptides makes it harder to identify what is helping or causing a reaction.
- Legal status is clear. TB-500 is not approved for human use, and buying it online carries quality and legal risk.
Frequently Asked Questions
How long should a TB-500 cycle be?
Most community protocols run 4 to 6 weeks, starting with two injections per week and tapering to once weekly. Some people describe 8- to 12-week schedules, but TB-500 is not FDA-approved for human use and no controlled human trial has established a correct cycle length.
Can you stack TB-500 and BPC-157 in the same cycle?
Many people do pair them, usually starting them a week or two apart so any reaction can be traced to a single peptide. TB-500 and BPC-157 use different dose sizes and injection frequencies, so their schedules are not interchangeable. Neither peptide is FDA-approved for human use.
Is TB-500 legal to buy in the United States?
TB-500 is not approved as a drug or a dietary supplement for human use, so it cannot legally be sold for human consumption. Vials labeled 'for research use only' are sold to laboratories, and buying them for personal use carries quality, legal, and safety risks.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.